Finch Therapeutics and OpenBiome have developed an orally administered microbial therapy for recurrent C. difficile infection.
FIN-403 harnesses the power of Phloral® to target delivery of healthy microbiota to the site of infection in the colon. FIN-403 demonstrated 88% per-protocol efficacy in an initial dose-finding study with 26 patients. DNA sequencing also showed successful and stable engraftment of the full diversity of the healthy microflora.
Our CEO, Bill Lindsay, was recently interviewed by Anju Ghangurde from Scrip Intelligence (Informa plc)
This tied in with a stimulating panel discussion on External Innovation at BioAsia 2018 in Hyderabad
Learn what Bill had to say about the future of microbiome-based therapies, oral delivery of biologics and more!
Copyright © 2018 Intract Pharma
Website Design by Creative Brand Design